Repurposing of drugs for triple negative breast cancer: an overview

Repurposing of drugs for triple negative breast cancer: an overview

Publication
Andrea Spini, Sandra Donnini, Pan Pantziarka, Sergio Crispino, Marina Ziche (2020). Repurposing of drugs for triple negative breast cancer: an overview. eCancer 13 July 2020, https://doi.org/10.3332/ecancer.2020.1071

Breast cancer (BC) is the most frequent cancer among women in the world and it remains a leading cause of cancer death in women globally. Among BCs, triple negative breast cancer (TNBC) is the most aggressive, and for its histochemical and molecular characteristics is also the one whose therapeutic opportunities are most limited.

The REpurposing Drugs in Oncology (ReDO) project investigated the potential use of off patent non-cancer drugs as sources of new cancer therapies. Repurposing of old non-cancer drugs, clinically approved, off patent and with known targets into oncological indications, offers potentially cheaper effective and safe drugs. In line with this project, this article describes a comprehensive overview of preclinical or clinical evidence of drugs included in the ReDO database and/or PubMed for repurposing as anticancer drugs into TNBC therapeutic treatments.

Read the full article here.